Merck unveils the Aptegra™ CHO genetic stability assay, a groundbreaking technology that revolutionizes biosafety testing in the pharmaceutical industry. By employing whole genome sequencing and bioinformatics, Aptegra™ accelerates biosafety evaluation, enabling faster delivery of new therapies to patients.